Evidence accumulating over the last decade has established the fundamental
role of vascular endothelial growth factor (VEGF) as a key regulator of nor
mal and abnormal angiogenesis. The biological effects of VEGF are mediated
by two tyrosine kinase receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2). The si
gnaling and biological properties of these two receptors are strikingly dif
ferent. VEGF is essential for early development of the vasculature to the e
xtent that inactivation of even a single allele of the VEGF gene results in
embryonic lethality. VEGF is also required for female reproductive functio
ns and endochondral bone formation. Substantial evidence also implicates VE
GF as an angiogenic mediator in tumors and intraocular neovascular syndrome
s, and numerous clinical trials are presently testing the hypothesis that i
nhibition of VEGF may have therapeutic value.